Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapy

PROTACs reach clinical development in inflammatory skin disease

Nature Medicine volume 29, pages 3006–3007 (2023)Cite this article

Subjects

A phase 1 trial of an IRAK4-targeted protein degrader in patients with chronic inflammatory skin diseases hits an important milestone for the safe application of this drug class beyond oncology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeted degradation of IRAK4 is pharmacologically different from IRAK4 kinase inhibition.

References

  1. Burslem, G. M. & Crews, C. M. Cell 181, 102–114 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chirnomas, D., Hornberger, K. R. & Crews, C. M. Nat. Rev. Clin. Oncol. 20, 265–278 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Ackerman, L. Nat. Med. https://doi.org/10.1038/s41591-023-02635-7 (2023).

  4. McElroy, W. T. Expert Opin. Ther. Pat. 29, 243–259 (2019).

    Article  CAS  PubMed  Google Scholar 

  5. Danto, S. I. et al. Arthritis Res. Ther. 21, 269 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Matyskiela, M. E. et al. Nat. Chem. Biol. 14, 981–987 (2018).

    Article  CAS  PubMed  Google Scholar 

  7. Donovan, K. A. et al. Elife 7, e38430 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ghobrial, I. M. & Rajkumar, S. V. J. Support. Oncol. 1, 194–205 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Volak, L. P. et al. Drug Metab. Dispos. 51, 792–803 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry, University of California, San Diego, CA, USA

    Fleur M. Ferguson

  2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA

    Fleur M. Ferguson

Authors
  1. Fleur M. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fleur M. Ferguson.

Ethics declarations

Competing interests

F.M.F. is a scientific co-founder and equity holder in Proximity Therapeutics, was recently a scientific advisory board (SAB) member for Triana Biomedicines, and is or recently was a consultant or received speaking honoraria from Eli Lilly and Co., RA Capital, Tocris BioTechne, Johnson & Johnson Innovative Medicine and Plexium Inc. The Ferguson lab receives or has received research funding from Ono Pharmaceutical Co. Ltd and Merck & Co.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferguson, F.M. PROTACs reach clinical development in inflammatory skin disease. Nat Med 29, 3006–3007 (2023). https://doi.org/10.1038/s41591-023-02622-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02622-y

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing